Navigation Links
Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing
Date:9/3/2008

SAN FRANCISCO, Sept. 3 /PRNewswire/ -- Osprey Pharmaceuticals U.S.A., a privately-held company focused on developing novel protein therapeutics that selectively target chemokine-activated leukocytes that are responsible for initiating and maintaining inflammatory diseases, announced today that the company has raised $11 million in its first round of venture capital funding. The financing was led by Burrill & Company with participation from Novo Nordisk Biotech Fund (Novo Nordisk's internal corporate venture fund), Yasuda Enterprise Development, GeneChem Therapeutics Venture Fund, BDC Venture Capital, Inc. and Western Technology Seed Investment Fund.

"With a lead compound poised to enter clinical studies and a rich pipeline of highly specific protein therapeutics designed to target chemokine-mediated inflammation, we are enthusiastic about the opportunity to invest in Osprey Pharmaceuticals U.S.A.," said John E. Hamer, Ph.D., Managing Partner of Burrill & Company on behalf of the company's investors. "The company has acquired a powerful drug discovery platform which has the potential to yield new high value therapeutics against inflammatory and autoimmune disease."

Osprey Pharmaceuticals U.S.A. will deploy these funds to advance the company's lead product, a therapeutic fusion protein known as CCL2-LPM, into a safety and proof-of-concept clinical trial. CCL2-LPM is designed to target the CCL2-CCR2 chemokine ligand and receptor axis, which play a significant role in inflammatory kidney diseases and other autoimmune and inflammatory conditions. Proceeds will also be applied to the discovery and development of additional therapeutics that have emerged from the company's proprietary platform for the discovery of therapeutic Leukocyte Population Modulators (LPMs). LPMs specifically target chemokine-activated leukocytes that drive and/or maintain a variety of inflammatory and autoimmune disorders.

"We are pleased to have received strong support
'/>"/>

SOURCE Osprey Pharmaceuticals U.S.A., Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Osprey Pharmaceuticals Names Jack M. Anthony as CEO
2. Jack Anthony to Resign From VaxGens Board After Accepting CEO Position at Osprey Pharmaceuticals
3. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
4. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
6. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
7. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
8. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
9. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
10. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
11. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 “Preparative ... Gas, HPLC, Flash), Consumables (Columns, Solvents, Buffers, Valves, ... Food & Agriculture) - Forecasts to 2019” provides ... challenges, opportunities, current market trends, and strategies impacting ...
(Date:12/24/2014)... Earlier this year in a June 24 international ... Stem Cell Technology Center, LLC ( ASCTC ) focused attention ... adult tissue stem cells. His title “Asymmetric Self-Renewal by ... Future,” embodied the essence of his message to congress participants. ...
(Date:12/24/2014)... 2014 On Friday, December 19, 2014, ... and Continuing Resolution Appropriations Act of 2015, which for ... receive funding through the Congressionally Directed Medical Research Programs ... Hydrocephalus Association (HA), working in conjunction with its allies ...
(Date:12/24/2014)... 23, 2014 The report provides ... definition, classification, application and industry overview. This report ... cost structure. Production is separated by regions, technology ... materials, equipment, downstream client survey, marketing channels, industry ...
Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... , LA JOLLA, Calif., Nov. 16 Fate ... a $30 million Series B financing led by OVP Venture ... a syndicate of corporate investors, including Astellas Venture Management, Genzyme ... co-leaders of the Company,s Series A financing, ARCH Venture Partners, ...
... Institute of Standards and Technology (NIST) have demonstrated ... run any program allowed by quantum mechanicsthe rules ... of information. The processor could be a module ... solve some important,problems that are intractable today. ...
... has received a 4.9 million funding boost from The ... used for invisibility ,cloaking, devices, sensitive security sensors that ... lenses that can be used to image tiny objects ... The new grant has been made to a team ...
Cached Biology Technology:Fate Therapeutics Closes $30 Million Series B Financing 2Fate Therapeutics Closes $30 Million Series B Financing 3Fate Therapeutics Closes $30 Million Series B Financing 4NIST demonstrates 'universal' programmable quantum processor 2NIST demonstrates 'universal' programmable quantum processor 3NIST demonstrates 'universal' programmable quantum processor 4£4.9 million to develop metamaterials for 'invisibility cloaks' and 'perfect lenses' 2£4.9 million to develop metamaterials for 'invisibility cloaks' and 'perfect lenses' 3
(Date:1/22/2015)... POINT ROBERTS, Washington , January 20, 2015 ... sectors including technology and tech stocks, releases video from the ... pickpocket and security consultant Apollo Robbins . ... about the Wocket™ biometric smart wallet, a product of NXT-ID, ...
(Date:1/22/2015)... CHARLOTTE, N.C. , Jan. 22, 2015 Infinisource has ... introduction of the G2 model. The G2 sets a higher ... company,s iSolved human capital management solution. With plug-and-play installation, touch ... G2 time clock provides a robust time collection solution for ...
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & ... http://photos.prnewswire.com/prnh/20130307/600769 ... introduced the fingerprint reading feature with the iPhone 5S. ...
Breaking Biology News(10 mins):Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 2Apollo Robbins Talks about the Illusion of Personal Safety and How Easily Your Wallet is Stolen; If a Wocket Wallet is Stolen the Thief Can't do Anything With it! 3Infinisource's NXG series sets new time clock standard 2iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2
... molecular fingerprints of what your cells are up to and ... cancer. You,ve likely heard about metabolites; your physician probably ... at your annual physical. Scientists suspect we have about 3,000 ... different compounds in our bodies. Dr. Sreekumar, ...
... 2009 A review by researchers at Northwestern University ... of the utility of probiotics in the treatment of ... 35624 was the only probiotic strain out of ... improve symptoms of IBS, including abdominal pain, bloating and ...
... at your desk and suddenly your heart is beating ... on fumes. It is a shocking, uncomfortable and frightening ... cause of sudden cardiac death or SCD, a condition ... States. Scientists are now closer to understanding what causes ...
Cached Biology News:Molecular fingerprints point the way to earlier cancer diagnosis and more targeted treatment 2Molecular fingerprints point the way to earlier cancer diagnosis and more targeted treatment 3Molecular fingerprints point the way to earlier cancer diagnosis and more targeted treatment 4Review of probiotic trial research finds only Bifantis able to claim efficacy for IBS symptoms 2Ten genes identified in connection with sudden cardiac death 2
... HM-4000 Multidizer is designed with a variety ... rotating - all in one unit. Shake, ... independently operating compartments allow for hybridization and ... motion , The upper chamber uses ...
... Savant's latest SpeedVac Concentrator, the SPD series ... a new modern twist., The SPD121P SpeedVac ... gauge for optimizing runs; preventing samples from ... stopped at the end-users preset level., Standard ...
... to create the ideal environment for nucleic acid ... , Variable speed control (10 to 15 ... be for washing or hybridizing , A ... the chamber, ,is situated above a touch sensitive ...
... latest edition to the famous SpeedVac concentrator ... large diameter exhaust port for improved drying ... precise setting and control of all important ... quantities and samples , STANDARD TEFLON ...
Biology Products: